Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VEGFA | P15692 | 5/20 | 0.59 |
| ▸ | EGLN1 | Q9GZT9 | 5/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.58 |
| ▸ | FAAH | O00519 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | PTGER3 | P43115 | 6/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17005944 | 0.92 | VEGFA (0.57) | VEGFAEGLN1ALDH1A1FAAHMAPT | |
| SCHEMBL1770528 | 0.91 | ALDH1A1 (0.73) | VEGFAEGLN1ALDH1A1FAAHMAPT | |
| SCHEMBL17005928 | 0.90 | VEGFA (0.59) | VEGFAEGLN1ALDH1A1MAPTMEN1 | |
| SCHEMBL1770463 | 0.89 | VEGFA (0.75) | VEGFAEGLN1ALDH1A1FAAHMAPT | |
| SCHEMBL17005914 | 0.88 | VEGFA (0.55) | VEGFAEGLN1ALDH1A1MAPTLMNA | |
| SCHEMBL16969539 | 0.88 | VEGFA (0.74) | VEGFAEGLN1ALDH1A1FAAHCYP2D6 | |
| SCHEMBL17005985 | 0.88 | VEGFA (0.62) | VEGFAEGLN1ALDH1A1MAPTMEN1 | |
| SCHEMBL17005904 | 0.88 | VEGFA (0.62) | VEGFAEGLN1ALDH1A1MAPTMEN1 | |
| SCHEMBL1770324 | 0.88 | KDM4E (0.58) | VEGFAEGLN1ALDH1A1LMNAMEN1 | |
| SCHEMBL17005969 | 0.88 | VEGFA (0.54) | VEGFAEGLN1ALDH1A1FAAHLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 111 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2853265-B1 | Methods for increasing the stabilization of hypoxia inducible factor-1 alpha | AERPIO THERAPEUTICS INC (US) | 2017-07-26 | — | — | EP | claimed |
| EP-2496084-B1 | COMPOSITIONS AND METHODS FOR TREATING COLITIS | AERPIO THERAPEUTICS INC (US) | 2015-06-10 | — | — | EP | claimed |
| US-9045495-B2 | Prolyl hydroxylase inhibitors | AERPIO THERAPEUTICS INC. (US) | 2015-06-02 | — | — | US | claimed |
| EP-2853265-A1 | Methods for increasing the stabilization of hypoxia inducible factor-1 alpha | Aerpio Therapeutics Inc. (US) | 2015-04-01 | — | — | EP | claimed |
| EP-2649998-B1 | Prolyl hydroxylase inhibitors | AERPIO THERAPEUTICS INC (US) | 2015-03-04 | — | — | EP | claimed |
| US-8883774-B2 | Methods for increasing the stabilization of hypoxia inducible factor-1 alpha | AERPIO THERAPEUTICS INC. (US) | 2014-11-11 | — | — | US | claimed |
| US-8778412-B2 | Methods for increasing the stabilization of hypoxia inducible factor-1 alpha | AERPIO THERAPEUTICS INC. (US) | 2014-07-15 | — | — | US | claimed |
| EP-2649998-A1 | Prolyl hydroxylase inhibitors | Aerpio Therapeutics Inc. (US) | 2013-10-16 | — | — | EP | claimed |
| US-8536181-B2 | Prolyl hydroxylase inhibitors | AERPIO THERAPEUTICS INC. (US) | 2013-09-17 | — | — | US | claimed |
| US-20130158010-A1 | METHODS FOR INCREASING THE STABILIZATION OF HYPOXIA INDUCIBLE FACTOR-1 ALPHA | AERPIO THERAPEUTICS INC. (US) | 2013-06-20 | — | — | US | claimed |
| US-20130158045-A1 | PROLYL HYDROXYLASE INHIBITORS | AERPIO THERAPEUTICS INC. (US) | 2013-06-20 | — | — | US | claimed |
| EP-2496236-B1 | PROLYL HYDROXYLASE INHIBITORS | AERPIO THERAPEUTICS INC (US) | 2013-05-01 | — | — | EP | claimed |
| US-8309537-B2 | Compositions and methods for treating colitis | AERPIO THERAPEUTICS INC. (US) | 2012-11-13 | — | — | US | claimed |
| EP-2496084-A1 | COMPOSITIONS AND METHODS FOR TREATING COLITIS | Aerpio Therapeutics Inc. (US) | 2012-09-12 | — | — | EP | claimed |
| EP-2496236-A1 | PROLYL HYDROXYLASE INHIBITORS | Aerpio Therapeutics Inc. (US) | 2012-09-12 | — | — | EP | claimed |
| WO-2011057121-A1 | COMPOSITIONS AND METHODS FOR TREATING COLITIS | AKEBIA THERAPEUTICS INC. (US) | 2011-05-12 | — | — | WO | claimed |
| US-20110110961-A1 | PROLYL HYDROXYLASE INHIBITORS | AERPIO THERAPEUTICS LLC | 2011-05-12 | — | — | US | claimed |
| US-20110112055-A1 | COMPOSITIONS AND METHODS FOR TREATING COLITIS | AERPIO THERAPEUTICS LLC | 2011-05-12 | — | — | US | claimed |
| WO-2011057115-A1 | PROLYL HYDROXYLASE INHIBITORS | AKEBIA THERAPEUTICS INC. (US) | 2011-05-12 | — | — | WO | claimed |
| US-20220185778-A1 | PROLYL HYDROXYLASE INHIBITORS | AERPIO THERAPEUTICS INC (US) | 2022-06-16 | — | — | US | disclosed |
| US-20220185778-A1 | PROLYL HYDROXYLASE INHIBITORS | AERPIO THERAPEUTICS INC (US) | 2022-06-16 | — | — | US | disclosed |
| CN-106232120-B | Process for preparing N-benzyl-3-hydroxy-4-substituted-pyridin-2- (1H) -ones | 爱尔皮奥治疗有限公司 | 2021-01-08 | — | — | CN | disclosed |
| EP-3698794-A1 | COMPOSITIONS AND METHODS FOR TREATING COLITIS | Aerpio Therapeutics, Inc. (US) | 2020-08-26 | — | — | EP | disclosed |
| US-10562854-B2 | Prolyl hydroxylase inhibitors | AERPIO THERAPEUTICS, INC. (US) | 2020-02-18 | — | — | US | disclosed |
| US-10562854-B2 | Prolyl hydroxylase inhibitors | AERPIO THERAPEUTICS, INC. (US) | 2020-02-18 | — | — | US | disclosed |
| EP-3603644-A1 | PROLYL HYDROXYLASE INHIBITORS | Aerpio Therapeutics, Inc. (US) | 2020-02-05 | — | — | EP | disclosed |
| EP-3603644-A1 | PROLYL HYDROXYLASE INHIBITORS | Aerpio Therapeutics, Inc. (US) | 2020-02-05 | — | — | EP | disclosed |
| EP-2952192-B1 | Prolyl hydroxylase inhibitors | AERPIO THERAPEUTICS INC (US) | 2019-05-15 | — | — | EP | disclosed |
| EP-2952192-B1 | Prolyl hydroxylase inhibitors | AERPIO THERAPEUTICS INC (US) | 2019-05-15 | — | — | EP | disclosed |
| EP-3107542-B1 | PROCESS FOR PREPARING N-BENZYL-3-HYDROXY-4-SUBSTITUTED-PYRIDIN-2-(1H)-ONES | AERPIO THERAPEUTICS INC (US) | 2019-05-01 | — | — | EP | disclosed |
| US-20190055198-A1 | PROLYL HYDROXYLASE INHIBITORS | AERPIO THERAPEUTICS LLC | 2019-02-21 | — | — | US | disclosed |
| US-20190055198-A1 | PROLYL HYDROXYLASE INHIBITORS | AERPIO THERAPEUTICS LLC | 2019-02-21 | — | — | US | disclosed |
| US-20170298019-A1 | PROLYL HYDROXYLASE INHIBITORS | AERPIO THERAPEUTICS LLC | 2017-10-19 | — | — | US | disclosed |
| US-20170298019-A1 | PROLYL HYDROXYLASE INHIBITORS | AERPIO THERAPEUTICS LLC | 2017-10-19 | — | — | US | disclosed |
| EP-2853265-B1 | Methods for increasing the stabilization of hypoxia inducible factor-1 alpha | AERPIO THERAPEUTICS INC (US) | 2017-07-26 | — | — | EP | disclosed |
| EP-2853265-B1 | Methods for increasing the stabilization of hypoxia inducible factor-1 alpha | AERPIO THERAPEUTICS INC (US) | 2017-07-26 | — | — | EP | disclosed |
| US-9540326-B2 | Prolyl hydroxylase inhibitors | AERPIO THERAPEUTICS, INC. (US) | 2017-01-10 | — | — | US | disclosed |
| US-9540326-B2 | Prolyl hydroxylase inhibitors | AERPIO THERAPEUTICS, INC. (US) | 2017-01-10 | — | — | US | disclosed |
| US-9540326-B2 | Prolyl hydroxylase inhibitors | AERPIO THERAPEUTICS, INC. (US) | 2017-01-10 | — | — | US | disclosed |
| EP-3107542-A1 | PROCESS FOR PREPARING N-BENZYL-3-HYDROXY-4-SUBSTITUTED-PYRIDIN-2-(1H)-ONES | Aerpio Therapeutics, Inc. (US) | 2016-12-28 | — | — | EP | disclosed |
| EP-2496082-B1 | METHODS FOR INCREASING THE STABILIZATION OF HYPOXIA INDUCIBLE FACTOR-1 ALPHA | AERPIO THERAPEUTICS INC (US) | 2016-10-12 | — | — | EP | disclosed |
| EP-2496082-B1 | METHODS FOR INCREASING THE STABILIZATION OF HYPOXIA INDUCIBLE FACTOR-1 ALPHA | AERPIO THERAPEUTICS INC (US) | 2016-10-12 | — | — | EP | disclosed |
| US-9388135-B2 | Process for preparing N-benzyl-3-hydroxy-4-substituted-pyridin-2-(1H)-ones | AERPIO THERAPEUTICS, INC. (US) | 2016-07-12 | — | — | US | disclosed |
| US-9278930-B2 | Methods for increasing the stabilization of hypoxia inducible factor-α | AERPIO THERAPEUTICS, INC. (US) | 2016-03-08 | — | — | US | disclosed |
| US-9278930-B2 | Methods for increasing the stabilization of hypoxia inducible factor-α | AERPIO THERAPEUTICS, INC. (US) | 2016-03-08 | — | — | US | disclosed |
| US-9278930-B2 | Methods for increasing the stabilization of hypoxia inducible factor-α | AERPIO THERAPEUTICS, INC. (US) | 2016-03-08 | — | — | US | disclosed |
| EP-2954899-A1 | COMPOSITIONS AND METHODS FOR TREATING COLITIS | Aerpio Therapeutics, Inc. (US) | 2015-12-16 | — | — | EP | disclosed |
| EP-2954899-A1 | COMPOSITIONS AND METHODS FOR TREATING COLITIS | Aerpio Therapeutics, Inc. (US) | 2015-12-16 | — | — | EP | disclosed |
| EP-2952192-A1 | Prolyl hydroxylase inhibitors | Aerpio Therapeutics Inc. (US) | 2015-12-09 | — | — | EP | disclosed |
| EP-2952192-A1 | Prolyl hydroxylase inhibitors | Aerpio Therapeutics Inc. (US) | 2015-12-09 | — | — | EP | disclosed |
| WO-2015126860-A1 | PROCESS FOR PREPARING N-BENZYL-3-HYDROXY-4-SUBSTITUTED-PYRIDIN-2-(1H)-ONES | AERPIO THERAPEUTICS, INC. (US) | 2015-08-27 | — | — | WO | disclosed |
| US-20150232425-A1 | PROCESS FOR PREPARING N-BENZYL-3-HYDROXY-4-SUBSTITUTED-PYRIDIN-2-(1H)-ONES | AERPIO THERAPEUTICS, INC. | 2015-08-20 | — | — | US | disclosed |
| US-20150218098-A1 | PROLYL HYDROXYLASE INHIBITORS | AERPIO THERAPEUTICS LLC | 2015-08-06 | — | — | US | disclosed |
| US-20150218098-A1 | PROLYL HYDROXYLASE INHIBITORS | AERPIO THERAPEUTICS LLC | 2015-08-06 | — | — | US | disclosed |
| US-20150218098-A1 | PROLYL HYDROXYLASE INHIBITORS | AERPIO THERAPEUTICS LLC | 2015-08-06 | — | — | US | disclosed |
| US-20150157617-A1 | METHODS FOR INCREASING THE STABILIZATION OF HYPOXIA INDUCIBLE FACTOR-1 ALPHA | AERPIO THERAPEUTICS LLC | 2015-06-11 | — | — | US | disclosed |
| US-20150157617-A1 | METHODS FOR INCREASING THE STABILIZATION OF HYPOXIA INDUCIBLE FACTOR-1 ALPHA | AERPIO THERAPEUTICS LLC | 2015-06-11 | — | — | US | disclosed |
| US-20150157617-A1 | METHODS FOR INCREASING THE STABILIZATION OF HYPOXIA INDUCIBLE FACTOR-1 ALPHA | AERPIO THERAPEUTICS LLC | 2015-06-11 | — | — | US | disclosed |
| EP-2496084-B1 | COMPOSITIONS AND METHODS FOR TREATING COLITIS | AERPIO THERAPEUTICS INC (US) | 2015-06-10 | — | — | EP | disclosed |
| EP-2496084-B1 | COMPOSITIONS AND METHODS FOR TREATING COLITIS | AERPIO THERAPEUTICS INC (US) | 2015-06-10 | — | — | EP | disclosed |
| US-9045495-B2 | Prolyl hydroxylase inhibitors | AERPIO THERAPEUTICS INC. (US) | 2015-06-02 | — | — | US | disclosed |
| US-9045495-B2 | Prolyl hydroxylase inhibitors | AERPIO THERAPEUTICS INC. (US) | 2015-06-02 | — | — | US | disclosed |
| US-9045495-B2 | Prolyl hydroxylase inhibitors | AERPIO THERAPEUTICS INC. (US) | 2015-06-02 | — | — | US | disclosed |
| US-8999971-B2 | Methods for increasing the stabilization of hypoxia inducible factor-1 alpha | AERPIO THERAPEUTICS INC. (US) | 2015-04-07 | — | — | US | disclosed |
| US-8999971-B2 | Methods for increasing the stabilization of hypoxia inducible factor-1 alpha | AERPIO THERAPEUTICS INC. (US) | 2015-04-07 | — | — | US | disclosed |
| US-8999971-B2 | Methods for increasing the stabilization of hypoxia inducible factor-1 alpha | AERPIO THERAPEUTICS INC. (US) | 2015-04-07 | — | — | US | disclosed |
| EP-2853265-A1 | Methods for increasing the stabilization of hypoxia inducible factor-1 alpha | Aerpio Therapeutics Inc. (US) | 2015-04-01 | — | — | EP | disclosed |
| EP-2649998-B1 | Prolyl hydroxylase inhibitors | AERPIO THERAPEUTICS INC (US) | 2015-03-04 | — | — | EP | disclosed |
| EP-2649998-B1 | Prolyl hydroxylase inhibitors | AERPIO THERAPEUTICS INC (US) | 2015-03-04 | — | — | EP | disclosed |
| US-20140364419-A1 | METHODS FOR INCREASING THE STABILIZATION OF HYPOXIA INDUCIBLE FACTOR-1 ALPHA | AERPIO THERAPEUTICS LLC | 2014-12-11 | — | — | US | disclosed |
| US-20140364419-A1 | METHODS FOR INCREASING THE STABILIZATION OF HYPOXIA INDUCIBLE FACTOR-1 ALPHA | AERPIO THERAPEUTICS LLC | 2014-12-11 | — | — | US | disclosed |
| US-20140364419-A1 | METHODS FOR INCREASING THE STABILIZATION OF HYPOXIA INDUCIBLE FACTOR-1 ALPHA | AERPIO THERAPEUTICS LLC | 2014-12-11 | — | — | US | disclosed |
| US-8883774-B2 | Methods for increasing the stabilization of hypoxia inducible factor-1 alpha | AERPIO THERAPEUTICS INC. (US) | 2014-11-11 | — | — | US | disclosed |
| US-8883774-B2 | Methods for increasing the stabilization of hypoxia inducible factor-1 alpha | AERPIO THERAPEUTICS INC. (US) | 2014-11-11 | — | — | US | disclosed |
| US-8883774-B2 | Methods for increasing the stabilization of hypoxia inducible factor-1 alpha | AERPIO THERAPEUTICS INC. (US) | 2014-11-11 | — | — | US | disclosed |
| US-8778412-B2 | Methods for increasing the stabilization of hypoxia inducible factor-1 alpha | AERPIO THERAPEUTICS INC. (US) | 2014-07-15 | — | — | US | disclosed |
| US-8778412-B2 | Methods for increasing the stabilization of hypoxia inducible factor-1 alpha | AERPIO THERAPEUTICS INC. (US) | 2014-07-15 | — | — | US | disclosed |
| US-8778412-B2 | Methods for increasing the stabilization of hypoxia inducible factor-1 alpha | AERPIO THERAPEUTICS INC. (US) | 2014-07-15 | — | — | US | disclosed |
| EP-2649998-A1 | Prolyl hydroxylase inhibitors | Aerpio Therapeutics Inc. (US) | 2013-10-16 | — | — | EP | disclosed |
| EP-2649998-A1 | Prolyl hydroxylase inhibitors | Aerpio Therapeutics Inc. (US) | 2013-10-16 | — | — | EP | disclosed |
| US-8536181-B2 | Prolyl hydroxylase inhibitors | AERPIO THERAPEUTICS INC. (US) | 2013-09-17 | — | — | US | disclosed |
| US-8536181-B2 | Prolyl hydroxylase inhibitors | AERPIO THERAPEUTICS INC. (US) | 2013-09-17 | — | — | US | disclosed |
| US-8536181-B2 | Prolyl hydroxylase inhibitors | AERPIO THERAPEUTICS INC. (US) | 2013-09-17 | — | — | US | disclosed |
| US-20130158010-A1 | METHODS FOR INCREASING THE STABILIZATION OF HYPOXIA INDUCIBLE FACTOR-1 ALPHA | AERPIO THERAPEUTICS INC. (US) | 2013-06-20 | — | — | US | disclosed |
| US-20130158010-A1 | METHODS FOR INCREASING THE STABILIZATION OF HYPOXIA INDUCIBLE FACTOR-1 ALPHA | AERPIO THERAPEUTICS INC. (US) | 2013-06-20 | — | — | US | disclosed |
| US-20130158010-A1 | METHODS FOR INCREASING THE STABILIZATION OF HYPOXIA INDUCIBLE FACTOR-1 ALPHA | AERPIO THERAPEUTICS INC. (US) | 2013-06-20 | — | — | US | disclosed |
| US-20130158045-A1 | PROLYL HYDROXYLASE INHIBITORS | AERPIO THERAPEUTICS INC. (US) | 2013-06-20 | — | — | US | disclosed |
| US-20130158045-A1 | PROLYL HYDROXYLASE INHIBITORS | AERPIO THERAPEUTICS INC. (US) | 2013-06-20 | — | — | US | disclosed |
| US-20130158045-A1 | PROLYL HYDROXYLASE INHIBITORS | AERPIO THERAPEUTICS INC. (US) | 2013-06-20 | — | — | US | disclosed |
| EP-2496236-B1 | PROLYL HYDROXYLASE INHIBITORS | AERPIO THERAPEUTICS INC (US) | 2013-05-01 | — | — | EP | disclosed |
| US-8309537-B2 | Compositions and methods for treating colitis | AERPIO THERAPEUTICS INC. (US) | 2012-11-13 | — | — | US | disclosed |
| US-8309537-B2 | Compositions and methods for treating colitis | AERPIO THERAPEUTICS INC. (US) | 2012-11-13 | — | — | US | disclosed |
| US-8309537-B2 | Compositions and methods for treating colitis | AERPIO THERAPEUTICS INC. (US) | 2012-11-13 | — | — | US | disclosed |
| EP-2496084-A1 | COMPOSITIONS AND METHODS FOR TREATING COLITIS | Aerpio Therapeutics Inc. (US) | 2012-09-12 | — | — | EP | disclosed |
| EP-2496082-A1 | METHODS FOR INCREASING THE STABILIZATION OF HYPOXIA INDUCIBLE FACTOR-1 ALPHA | Aerpio Therapeutics Inc. (US) | 2012-09-12 | — | — | EP | disclosed |
| EP-2496236-A1 | PROLYL HYDROXYLASE INHIBITORS | Aerpio Therapeutics Inc. (US) | 2012-09-12 | — | — | EP | disclosed |
| WO-2011057121-A1 | COMPOSITIONS AND METHODS FOR TREATING COLITIS | AKEBIA THERAPEUTICS INC. (US) | 2011-05-12 | — | — | WO | disclosed |
| WO-2011057121-A1 | COMPOSITIONS AND METHODS FOR TREATING COLITIS | AKEBIA THERAPEUTICS INC. (US) | 2011-05-12 | — | — | WO | disclosed |
| WO-2011057121-A1 | COMPOSITIONS AND METHODS FOR TREATING COLITIS | AKEBIA THERAPEUTICS INC. (US) | 2011-05-12 | — | — | WO | disclosed |
| US-20110112055-A1 | COMPOSITIONS AND METHODS FOR TREATING COLITIS | AERPIO THERAPEUTICS LLC | 2011-05-12 | — | — | US | disclosed |
| US-20110112055-A1 | COMPOSITIONS AND METHODS FOR TREATING COLITIS | AERPIO THERAPEUTICS LLC | 2011-05-12 | — | — | US | disclosed |
| US-20110110961-A1 | PROLYL HYDROXYLASE INHIBITORS | AERPIO THERAPEUTICS LLC | 2011-05-12 | — | — | US | disclosed |
| US-20110110961-A1 | PROLYL HYDROXYLASE INHIBITORS | AERPIO THERAPEUTICS LLC | 2011-05-12 | — | — | US | disclosed |
| US-20110111058-A1 | METHODS FOR INCREASING THE STABILIZATION OF HYPOXIA INDUCIBLE FACTOR-1 ALPHA | AERPIO THERAPEUTICS LLC | 2011-05-12 | — | — | US | disclosed |
| US-20110111058-A1 | METHODS FOR INCREASING THE STABILIZATION OF HYPOXIA INDUCIBLE FACTOR-1 ALPHA | AERPIO THERAPEUTICS LLC | 2011-05-12 | — | — | US | disclosed |
| US-20110112055-A1 | COMPOSITIONS AND METHODS FOR TREATING COLITIS | AERPIO THERAPEUTICS LLC | 2011-05-12 | — | — | US | disclosed |
| US-20110110961-A1 | PROLYL HYDROXYLASE INHIBITORS | AERPIO THERAPEUTICS LLC | 2011-05-12 | — | — | US | disclosed |
| US-20110111058-A1 | METHODS FOR INCREASING THE STABILIZATION OF HYPOXIA INDUCIBLE FACTOR-1 ALPHA | AERPIO THERAPEUTICS LLC | 2011-05-12 | — | — | US | disclosed |
| WO-2011057112-A1 | METHODS FOR INCREASING THE STABILIZATION OF HYPOXIA INDUCIBLE FACTOR-1 ALPHA | AKEBIA THERAPEUTICS INC. (US) | 2011-05-12 | — | — | WO | disclosed |
| WO-2011057112-A1 | METHODS FOR INCREASING THE STABILIZATION OF HYPOXIA INDUCIBLE FACTOR-1 ALPHA | AKEBIA THERAPEUTICS INC. (US) | 2011-05-12 | — | — | WO | disclosed |
| WO-2011057115-A1 | PROLYL HYDROXYLASE INHIBITORS | AKEBIA THERAPEUTICS INC. (US) | 2011-05-12 | — | — | WO | disclosed |
| WO-2011057115-A1 | PROLYL HYDROXYLASE INHIBITORS | AKEBIA THERAPEUTICS INC. (US) | 2011-05-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170298019-A1 | PROLYL HYDROXYLASE INHIBITORS | HIF1AN, HIF1A, EGLN2 | VEGFA 551/4885EGLN1 5/4885ALDH1A1 652/4885 |
| US-20150157617-A1 | METHODS FOR INCREASING THE STABILIZATION OF HYPOXIA INDUCIBLE FACTOR-1 ALPHA | HIF1A, HIF1AN, EGLN3 | VEGFA 20/4885EGLN1 8/4885ALDH1A1 505/4885 |
| US-20110112055-A1 | COMPOSITIONS AND METHODS FOR TREATING COLITIS | ALPI, SI, SLC10A2 | VEGFA 4546/4885EGLN1 2861/4885ALDH1A1 780/4885 |
| US-20130158045-A1 | PROLYL HYDROXYLASE INHIBITORS | HIF1AN, HIF1A, EGLN2 | VEGFA 551/4885EGLN1 5/4885ALDH1A1 652/4885 |
| US-20150232425-A1 | PROCESS FOR PREPARING N-BENZYL-3-HYDROXY-4-SUBSTITUTED-PYRIDIN-2-(1H)-ONES | CYP4B1, CYP8B1, HPD | VEGFA 4681/4885EGLN1 102/4885ALDH1A1 1501/4885 |
| US-20190055198-A1 | PROLYL HYDROXYLASE INHIBITORS | HIF1AN, HIF1A, EGLN2 | VEGFA 551/4885EGLN1 5/4885ALDH1A1 652/4885 |
| US-20220185778-A1 | PROLYL HYDROXYLASE INHIBITORS | HIF1AN, HIF1A, EGLN2 | VEGFA 551/4885EGLN1 5/4885ALDH1A1 652/4885 |
| US-20110111058-A1 | METHODS FOR INCREASING THE STABILIZATION OF HYPOXIA INDUCIBLE FACTOR-1 ALPHA | HIF1A, HIF1AN, EGLN3 | VEGFA 20/4885EGLN1 8/4885ALDH1A1 505/4885 |
| US-20150218098-A1 | PROLYL HYDROXYLASE INHIBITORS | HIF1AN, HIF1A, EGLN2 | VEGFA 551/4885EGLN1 5/4885ALDH1A1 652/4885 |
| US-20140364419-A1 | METHODS FOR INCREASING THE STABILIZATION OF HYPOXIA INDUCIBLE FACTOR-1 ALPHA | HIF1A, HIF1AN, EGLN3 | VEGFA 20/4885EGLN1 8/4885ALDH1A1 505/4885 |
| US-20130158010-A1 | METHODS FOR INCREASING THE STABILIZATION OF HYPOXIA INDUCIBLE FACTOR-1 ALPHA | HIF1A, HIF1AN, EGLN3 | VEGFA 20/4885EGLN1 8/4885ALDH1A1 505/4885 |
| US-20110110961-A1 | PROLYL HYDROXYLASE INHIBITORS | HIF1AN, HIF1A, EGLN2 | VEGFA 551/4885EGLN1 5/4885ALDH1A1 652/4885 |
| US-10562854-B2 | Prolyl hydroxylase inhibitors | HIF1AN, HIF1A, EGLN2 | VEGFA 551/4885EGLN1 5/4885ALDH1A1 652/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.